NCT04383483 is a clinical trial of COVICU in Coronavirus as the Cause of Diseases Classified Elsewhere, sponsored by Bursa Yuksek Ihtisas Training and Research Hospital.

Who is sponsoring NCT04383483?

NCT04383483 is sponsored by Bursa Yuksek Ihtisas Training and Research Hospital.

What drugs are being tested in NCT04383483?

Interventions in NCT04383483: COVICU.

What condition does NCT04383483 study?

NCT04383483 studies Coronavirus as the Cause of Diseases Classified Elsewhere.

Is NCT04383483 still recruiting?

NCT04383483 is currently status unknown. Last updated 29 March 2021.

Last reviewed 2021-03-29 · How we verify

NCT04383483

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CoV-ICU Score, Intensive Care Unit, SARS-CoV-2

Status unknown Last updated 29 March 2021

What this trial tests

trial testing COVICU in Coronavirus as the Cause of Diseases Classified Elsewhere in 100 participants. Status unknown.

Timeline

15 June 2020

Primary endpoint
31 January 2022

28 February 2022

Quick facts

Lead sponsor	Bursa Yuksek Ihtisas Training and Research Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	100
Start date	15 June 2020
Primary completion	31 January 2022
Estimated completion	28 February 2022
Sites	1 location across Turkey (Türkiye)

Drugs / interventions tested

COVICU

Conditions studied

Coronavirus as the Cause of Diseases Classified Elsewhere — all drugs for Coronavirus as the Cause of Diseases Classified Elsewhere →

Sponsor

Bursa Yuksek Ihtisas Training and Research Hospital

Who can join

Adults 18 to 100, any sex, with Coronavirus as the Cause of Diseases Classified Elsewhere. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In the course of COVID disease, some patients need intensive care treatment. We aim to find an answer to the question of whether the patient's CRP, ferritin, D-dimer, Oxygen Saturation, lymphocyte count, and body mass index can be used as a criterion for admitting patients with COVID to the intensive see unit.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Bursa Yuksek Ihtisas Training and Research Hospital trials

Trials by the same sponsor.

NCT07397663 — Ultrasound-Based Prediction of Hemodynamic Instability During CVVHDF Initiation · not yet recruiting
NCT07346885 — Lumbar-Sacral Plexus Block vs Fascia Iliaca Block Plus Low-Dose Spinal Anesthesia for Femoral Neck Fracture Surgery · NA · active not recruiting
NCT07346872 — EXORA Block vs Epidural Analgesia in Gynecological Surgery · NA · active not recruiting
NCT07314125 — ChatGPT-5 vs. CDSS for Drug-Drug Interactions in ICU · completed
NCT07452367 — Optic Nerve Sheath Diameter and Cognitive Outcomes in Bentall Surgery · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04383483 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bursa Yuksek Ihtisas Training and Research Hospital
Last refreshed: 29 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04383483.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing